ES2076160T3 - Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante. - Google Patents

Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante.

Info

Publication number
ES2076160T3
ES2076160T3 ES88308124T ES88308124T ES2076160T3 ES 2076160 T3 ES2076160 T3 ES 2076160T3 ES 88308124 T ES88308124 T ES 88308124T ES 88308124 T ES88308124 T ES 88308124T ES 2076160 T3 ES2076160 T3 ES 2076160T3
Authority
ES
Spain
Prior art keywords
recombinant dna
subunits
toxin subunit
bordetella
analogs obtained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88308124T
Other languages
English (en)
Other versions
ES2076160T5 (es
Inventor
Iii Walter Neal Burnette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26788722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2076160(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ES2076160T3 publication Critical patent/ES2076160T3/es
Application granted granted Critical
Publication of ES2076160T5 publication Critical patent/ES2076160T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/10Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

EL DESARROLLO DE SUBUNIDADES Y ANALOGOS DE SUBUNIDADES DE LA EXOTOXINA DE BORDETELLA POR MEDIO DE TECNICAS DE RECOMBINACION DE DNA PROPORCIONA PRODUCTOS ADECUADOS PARA LA FABRICACION DE VACUNAS QUE RETIENEN SU ACTIVIDAD BIOLOGICA, SON ALTAMENTE INMUNOGENICOS Y PUEDEN PROPORCIONAR PROTECCION ANTE EL RIESGO DE ENFERMEDAD. MODIFICACIONES EN LAS SUBUNIDADES PRODUCIDAS A TRAVES DE INGENIERIA GENETICA PUEDEN DAR COMO RESULTADO PRODUCTOS QUE RETIENEN SU CAPACIDAD INMUNOGENICA, PERO QUE CARECEN DE LA ACTIVIDAD ENZIMATICA ASOCIADA CON LA TOXINA.
ES88308124T 1987-09-04 1988-09-01 Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante. Expired - Lifetime ES2076160T5 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9430787A 1987-09-04 1987-09-04
US94307 1987-09-04
US23248288A 1988-08-17 1988-08-17
US232482 1988-08-17

Publications (2)

Publication Number Publication Date
ES2076160T3 true ES2076160T3 (es) 1995-11-01
ES2076160T5 ES2076160T5 (es) 2004-12-01

Family

ID=26788722

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88308124T Expired - Lifetime ES2076160T5 (es) 1987-09-04 1988-09-01 Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante.

Country Status (16)

Country Link
US (1) US5773600A (es)
EP (2) EP0306318B2 (es)
JP (1) JP2918895B2 (es)
KR (1) KR0168039B1 (es)
CN (1) CN1033866C (es)
AT (1) ATE125568T1 (es)
CA (1) CA1341560C (es)
DE (1) DE3854213T3 (es)
DK (1) DK175821B1 (es)
ES (1) ES2076160T5 (es)
FI (1) FI101632B1 (es)
GR (1) GR3017497T3 (es)
IE (1) IE69753B1 (es)
IL (3) IL87608A0 (es)
NO (2) NO301844B1 (es)
WO (1) WO1989001976A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925546A (en) * 1987-11-02 1999-07-20 Chiron S.P.A. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
US6713072B1 (en) * 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
US5332583A (en) * 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) * 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
CA2009991A1 (en) * 1989-02-15 1990-08-15 Witold Cieplak Pertussis toxin gene: cloning and expression of protective antigen
US7232671B2 (en) * 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
EP0396964B1 (en) * 1989-04-28 1995-09-06 SCLAVO S.p.A. Pertussis toxin mutants, bordetella strains capable of producing such mutants and their use in the development of antipertussis vaccines
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
EP1234580A1 (en) * 1995-05-04 2002-08-28 Aventis Pasteur Limited Acellular Pertussis Vaccines and Methods of Preparation Thereof
WO1997043407A1 (en) * 1996-05-10 1997-11-20 Phylomed Corporation Methods for oxidizing disulfide bonds using ozone
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
CA2590906C (en) * 2004-12-17 2017-01-03 Nvi Nederlands Vaccininstituut Deacylation of lps in gram negative bacteria
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
MX343356B (es) 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
MX362793B (es) 2013-03-08 2019-02-13 Janssen Vaccines & Prevention Bv Vacuna acelular contra pertussis.
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
US20220047690A1 (en) * 2018-10-15 2022-02-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Vaccine polypeptide compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FR2590483B1 (fr) * 1985-11-22 1988-12-09 Pasteur Institut Antigenes purifies ayant des proprietes vaccinantes contre b. pertussis, moyens notamment adns recombinants pour les produire et compositions de vaccins les contenant
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
EP0275689B1 (en) * 1986-12-23 1992-09-02 The Board Of Trustees Of The Leland Stanford Junior University Modified pertussis exotoxin
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
IT1223529B (it) * 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse

Also Published As

Publication number Publication date
FI101632B (fi) 1998-07-31
KR890701758A (ko) 1989-12-21
IE69753B1 (en) 1996-10-02
EP0306318B2 (en) 2004-04-28
CN1033866C (zh) 1997-01-22
JP2918895B2 (ja) 1999-07-12
AU623867B2 (en) 1992-05-28
NO301844B1 (no) 1997-12-15
JPH04501051A (ja) 1992-02-27
NO972642L (no) 1997-07-28
IL87608A0 (en) 1989-01-31
FI101632B1 (fi) 1998-07-31
NO972642D0 (no) 1997-06-09
NO325016B1 (no) 2008-01-14
NO891842L (no) 1989-06-21
IL103121A (en) 1995-08-31
CN1033072A (zh) 1989-05-24
IL103121A0 (en) 1993-02-21
EP0306318B1 (en) 1995-07-26
NO891842D0 (no) 1989-05-03
EP0629696A1 (en) 1994-12-21
KR0168039B1 (ko) 1999-01-15
DE3854213T2 (de) 1995-12-07
DE3854213D1 (de) 1995-08-31
FI892131A (fi) 1989-05-03
CA1341560C (en) 2007-10-30
ATE125568T1 (de) 1995-08-15
DE3854213T3 (de) 2004-10-21
FI892131A0 (fi) 1989-05-03
DK216289D0 (da) 1989-05-03
WO1989001976A1 (en) 1989-03-09
US5773600A (en) 1998-06-30
EP0306318A1 (en) 1989-03-08
AU2386488A (en) 1989-03-31
DK175821B1 (da) 2005-03-14
GR3017497T3 (en) 1995-12-31
ES2076160T5 (es) 2004-12-01
IE882668L (en) 1989-03-04
DK216289A (da) 1989-06-30

Similar Documents

Publication Publication Date Title
ES2076160T3 (es) Analogos de las subunidades de la toxina de bordetella obtenidos a partir de adn recombinante.
ES2156110T3 (es) Analogos de sub-unidades de toxina del colera derivados de adn recombinante.
ES2128320T3 (es) Metodo criptocitotoxico binario de produccion de semilla hibrida.
AR020735A1 (es) Un procedimiento para la obtencion de un polipeptido glucosilado a partir de celulas eucarioticas
CO5070674A1 (es) Vacunas con un oligonucleotido cpg como adyuvante
CL2004001483A1 (es) Procedimiento para producir una celula vegetal y un cultivo de estas, que son resistentes o tolerantes a un herbicida que inhibe a la glutamina sintetasa mediante la introduccion de un gen que codifica una acetil-transferasa; metodo para producir una
ES2119250T3 (es) Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos.
FI881185A0 (fi) Human mangan-superoxiddismutas (hmn-sod).
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
ES2094111T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion que utilizan celulas modificadas por ingenieria genetica y composiciones farmaceuticas que las contienen.
IL196900A (en) Autologous T cell vaccine compositions
AR027765A1 (es) Expresion y purificacion de polipeptidos bioactivos autenticos a partir de plantas
ATE348876T1 (de) Verfahren zur vermehrung von natürlichen killerzellen
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
DE3850774D1 (de) Rinder-interleukin-1-alpha.
RS75604A (en) Microorganismus as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors
ATE246935T1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
ES2059472T3 (es) Plantas con color de las flores modificado y procedimiento biotecnologico para su obtencion.
ATE414141T1 (de) Verfahren zur kultivierung humaner chondrozyten
DE69837047D1 (de) Verfahren zur herstellung verzweigtkettiger fettsäuren mittels genetisch modifizierter pflanzen
ES2062006T3 (es) Un psti humano modificado.
ES2053766T3 (es) Metodo para aumentar la expresion de un gen.
DE60033562D1 (de) Künstliche promotoren zür protein expression in pflanzen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 306318

Country of ref document: ES